Table A1.

Study Drug Exposure

Drug Exposure Factor	Placebo (n = 47)	Linifanib 7.5 mg (n = 42)*	Linifanib 12.5 mg (n = 47)
Treatment duration, days
Median	159.0	153.0	126.0
Range	2.0-465.0	6.0-525.0	6.0-503.0
Dose-intensity, %
Median	100.0	99.5	94.9
Range	63.4-119.5	60.3-104.6	51.9-100.0
Dose modifications
No. of patients	35	23	22
%	74.5	54.8	46.8
Any dose interruption
No. of patients	12	19	25
%	25.5	45.2	53.2
Any dose reduction
No. of patients	1	6	16
%	2.1	14.3	34.0
Paclitaxel
No. of cycles
Median	6.0	5.0	5.0
Range	1.0-6.0	1.0-6.0	1.0-6.0
Six cycles
No. of patients	28	19	20
%	59.6	45.2	43.5
Carboplatin
No. of cycles
Median	6.0	5.0	5.0
Range	1.0-6.0	1.0-6.0	1.0-6.0
Six cycles
No. of patients	29	19	20
%	61.7	45.2	42.6

^*Two patients did not receive a dose of linifanib and were not included in the exposure or safety analyses.